DMRA Damora Therapeutics, Inc. - Common Stock
NASDAQ · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 10, 2026
$20,65
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$18,5952-Wochen-Tief
$34,8952-Wochen-Hoch
Marktkapitalisierung (MRQ)
$1.27B
EPS
$3.98
Ihre Abzeichen
52W-Spanne
$19–$35
Analystenbewertung
BUY
Kursziel
$47
P/E
·
ROE
-167.0%
Nettogewinnmarge
-17981.1%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
DMRA Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$20.65
Marktkapitalisierung (MRQ)
$1.27B
EPS
$3.98
ROE
-167.0%
52W-Spanne
$19–$35
DMRA Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 30. August 2024 | 1-for-25 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
EPS$3.982021-12-31 → 2025-12-31
Freier Cashflow·2021-12-31 → 2022-12-31
Nettogewinnmarge-17981.1%2021-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | DMRA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| K/B (MRQ) | 2.5 | · | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | DMRA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Operating Margin (Betriebsgewinnmarge) | -18069.6%5-Jahres-Durchschnitt ≈-13005.2% | ≈-13005.2% | · | · | |
| EBITDA Margin (EBITDA-Marge) | -18069.6%5-Jahres-Durchschnitt ≈-13005.2% | ≈-13005.2% | · | · | |
| Pretax Margin (Vorgewinnmarge) | -17976.8%5-Jahres-Durchschnitt ≈-12898.4% | ≈-12898.4% | · | · | |
| Net Profit Margin (Nettogewinnmarge) | -17981.1%5-Jahres-Durchschnitt ≈-12900.3% | ≈-12900.3% | · | · | |
| ROA | -151.2%5-Jahres-Durchschnitt ≈-79.1% | ≈-79.1% | · | · | |
| ROE | -167.0%5-Jahres-Durchschnitt ≈-105.4% | ≈-105.4% | · | · | |
| ROIC | -87.8%5-Jahres-Durchschnitt ≈-99.1% | ≈-99.1% | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | DMRA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 19.75-Jahres-Durchschnitt ≈12.7 | ≈12.7 | · | · | |
| Quick Ratio | 12.85-Jahres-Durchschnitt ≈11.6 | ≈11.6 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | DMRA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 38.3%5-Jahres-Durchschnitt ≈121.2% | ≈121.2% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 17.4% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | DMRA | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.05-Jahres-Durchschnitt ≈0.0 | ≈0.0 | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
421.9%
Nächster Bericht
Nov 04, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 3, 2026 | $-0.39 | $-0.43 | 10.2% |
| 31. März 2026 | $-0.62 | $-0.40 | -56.8% | |
| 31. Dezember 2025 | $2.70 | $-0.11 | 2581.6% | |
| 31. Dezember 2024 | $-5.23 | $-3.03 | -72.6% | |
| 30. September 2024 | $-3.39 | $-4.18 | 19.0% | |
| 30. Juni 2024 | $-4.00 | $-8.03 | 50.2% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| R&D Expense | $27M | $6M | $24M | $48M | $38M | $25M | $20M | |
| SG&A Expense | $10M | $10M | $13M | $13M | $14M | $9M | $2M | |
| Operating Expenses | $211M | $22M | $40M | $61M | $52M | $34M | $39M | |
| Operating Income | $-211M | $-22M | $-40M | $-61M | $-52M | $-34M | $39M | |
| Other Non-op | $1M | $862.0K | $2M | $-417.0K | $475.0K | $-1M | $2M | |
| Pretax Income | $-210M | $-21M | $-38M | $-62M | $-52M | $-35M | $-37M | |
| Income Tax | $50.0K | $41.0K | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-210M | $-21M | $-38M | $-62M | $-52M | $-35M | $-37M | |
| EPS (Basic) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | · | · | |
| EPS (Diluted) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | · | · | |
| Shares (Basic) | 1,363,005 | 1,157,149 | 1,062,873 | 25,409,123 | 25,261,832 | · | · | |
| Shares (Diluted) | 1,363,005 | 1,157,149 | 1,062,873 | 25,409,123 | 25,261,832 | · | · | |
| EBITDA | $-211M | $-22M | $-40M | $-61M | $-52M | $34M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $258M | $14M | $21M | $33M | $63M | $164M | $11M | |
| Short-term Investments | · | · | $12M | $27M | $38M | · | · | |
| Prepaid Expense | $3M | $3M | $4M | $4M | $10M | $6M | $5M | |
| Current Assets | $260M | $17M | $37M | $64M | $110M | $169M | $56M | |
| PP&E (Net) | $36.0K | $57.0K | $78.0K | $357.0K | $203.0K | · | · | |
| PP&E (Gross) | $108.0K | $107.0K | $107.0K | $419.0K | $223.0K | · | · | |
| Accum. Depreciation | $72.0K | $50.0K | $29.0K | $62.0K | $20.0K | · | · | |
| Other Non-current Assets | $104.0K | $163.0K | $1M | $2M | $2M | $1M | · | |
| Total Assets | $261M | $17M | $38M | $73M | $122M | $172M | $57M | |
| Accounts Payable | $444.0K | $377.0K | $2M | $3M | $2M | $3M | $3M | |
| Accrued Liabilities | $2M | $820.0K | $4M | $8M | $3M | $3M | $5M | |
| Current Liabilities | $20M | $1M | $6M | $11M | $5M | $6M | $8M | |
| Capital Leases | $53.0K | $61.0K | $66.0K | $328.0K | $448.0K | $541.0K | $211.0K | |
| Other Non-current Liabilities | $81.0K | $43.0K | · | · | · | · | · | |
| Total Liabilities | $20M | $1M | $6M | $11M | $5M | $6M | $8M | |
| Paid-in Capital | $311M | $292M | $288M | $280M | $274M | $269M | $826.0K | |
| Retained Earnings | $-487M | $-278M | $-256M | $-218M | $-156M | $-104M | $-70M | |
| AOCI | $802.0K | $97.0K | $380.0K | $-244.0K | $-320.0K | $674.0K | $-2M | |
| Stockholders' Equity | $240M | $16M | $32M | $62M | $117M | $165M | $-71M | |
| Liabilities + Equity | $261M | $17M | $38M | $73M | $122M | $172M | $57M | |
| Shares Outstanding | 1,597,321 | 1,316,989 | 1,084,509 | 25,652,392 | 25,261,832 | 25,261,832 | 259,966 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $998.0K | $3M | $5M | $6M | $4M | $982.0K | · | |
| Restructuring | · | $968.0K | $3M | · | · | · | · | |
| Operating Cash Flow | $-7M | $-19M | $-37M | $-43M | $-52M | $-38M | $-19M | |
| CapEx | · | · | · | $196.0K | $223.0K | · | · | |
| Investing Cash Flow | $-17M | $12M | $22M | $12M | $-48M | · | $-326.0K | |
| Stock Issued | · | · | $3M | $507.0K | · | · | · | |
| Net Stock Activity | · | · | $3M | $507.0K | · | · | · | |
| Financing Cash Flow | $267M | · | $3M | $507.0K | · | $187M | · | |
| Taxes Paid | $5.0K | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | $-43M | $-53M | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18069.6% | -2637.4% | -2362.6% | -8477.4% | -33478.8% | · | · | |
| Net Margin | -17981.1% | -2540.2% | -2270.5% | -8535.2% | -33174.4% | · | · | |
| Pretax Margin | -17976.8% | -2535.3% | -2270.5% | -8535.2% | -33174.4% | · | · | |
| EBITDA Margin | -18069.6% | -2637.4% | -2362.6% | -8477.4% | -33478.8% | · | · | |
| ROA | -151.2% | -77.5% | -68.8% | -63.1% | -35.2% | -30.5% | · | |
| ROE | -167.0% | -116.6% | -110.0% | -91.6% | -41.9% | -94.5% | · | |
| ROIC | -87.8% | -140.9% | -123.4% | -99.1% | -44.5% | 20.3% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.0 | 14.1 | 6.3 | 5.8 | 24.2 | 30.4 | · | |
| Quick Ratio | 12.8 | 11.8 | 5.7 | 5.4 | 22.0 | 29.4 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $150.49 | $12.02 | $1.19 | $2.41 | $4.64 | $6.55 | · | |
| Revenue / Share | $0.86 | $0.73 | $0.06 | $0.03 | · | · | · | |
| Cash Flow / Share | $-4.93 | $-16.09 | $-1.39 | $-1.69 | · | · | · | |
| Cash / Share | $161.29 | $10.76 | $0.79 | $1.28 | $2.48 | $6.48 | · | |
| Dividend / Share | $0.00 | $0.00 | · | · | $0.00 | $0.00 | · | |
| Dividend Paid / Share | · | · | · | · | $0.00 | $0.00 | · | |
| EPS (TTM) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 38.3% | -50.0% | 133.9% | 362.8% | · | · | · | |
| Revenue CAGR 3Y | 17.4% | 75.5% | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1M | $844.0K | $2M | $722.0K | $156.0K | · | · | |
| Net Income TTM | $-210M | $-21M | $-38M | $-62M | $-52M | $-35M | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $26M | $24M | $23M | $1M | $1M | $678.0K | $1M | $1M | $2M | $2M | $3M | $3M | $8M | $10M | $11M | $10M | |
| SG&A Expense | $9M | $7M | $4M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Operating Expenses | $35M | $31M | $202M | $3M | $3M | $3M | $7M | $4M | $6M | $6M | $7M | $9M | $11M | $13M | $14M | $14M | |
| Operating Income | $-35M | $-31M | $-202M | $-3M | $-3M | $-3M | $-7M | $-4M | $-6M | $-6M | $-7M | $-9M | $-11M | $-13M | $-14M | $-14M | |
| Other Non-op | $4M | $3M | $1M | $23.0K | $-12.0K | $68.0K | $353.0K | $-36.0K | $281.0K | $264.0K | $196.0K | $447.0K | $415.0K | $498.0K | $-544.0K | $-108.0K | |
| Pretax Income | $-31M | $-28M | $-201M | $-3M | $-3M | $-3M | $-7M | $-4M | $-5M | $-5M | $-6M | $-8M | $-11M | · | · | · | |
| Income Tax | $255.0K | $42.0K | $44.0K | $0 | $4.0K | $2.0K | $-8.0K | $7.0K | $42.0K | · | · | · | · | · | · | · | |
| Net Income | $-31M | $-28M | $-201M | $-3M | $-3M | $-3M | $-7M | $-4M | $-5M | $-5M | $-6M | $-8M | $-11M | $-13M | $-14M | $-14M | |
| EPS (Basic) | $-0.39 | $-0.62 | $10.86 | $-2.36 | $-2.60 | $-1.92 | $-5.17 | $-3.39 | $-4.92 | $-5.05 | $-27.66 | $-7.50 | $-0.41 | $-0.51 | $-0.55 | $-0.54 | |
| EPS (Diluted) | $-0.39 | $-0.62 | $10.86 | $-2.36 | $-2.60 | $-1.92 | $-5.17 | $-3.39 | $-4.92 | $-5.05 | $-27.66 | $-7.50 | $-0.41 | $-0.51 | $-0.55 | $-0.54 | |
| Shares (Basic) | 61,117,057 | 34,299,182 | · | 1,327,039 | 1,322,553 | 1,322,011 | · | 1,144,978 | 1,084,622 | 1,084,509 | · | 1,084,191 | 26,375,076 | 25,672,902 | · | 25,491,786 | |
| Shares (Diluted) | 61,117,057 | 34,299,182 | · | 1,327,039 | 1,322,553 | 1,322,011 | · | 1,144,978 | 1,084,622 | 1,084,509 | · | 1,084,191 | 26,375,076 | 25,672,902 | · | 25,491,786 | |
| EBITDA | $-35M | $-31M | · | $-3M | $-3M | $-3M | · | $-4M | $-6M | $-6M | · | $-9M | $-11M | $-13M | · | $-14M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $541M | $533M | $258M | $8M | $10M | $12M | $14M | $20M | $23M | $21M | $21M | $23M | $23M | $25M | $33M | $28M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $6M | $12M | $21M | $29M | $28M | $27M | $41M | |
| Prepaid Expense | $3M | $3M | $3M | $2M | $3M | $3M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | $4M | $4M | $2M | |
| Current Assets | $544M | $535M | $260M | $10M | $13M | $15M | $17M | $21M | $25M | $31M | $37M | $47M | $55M | $57M | $64M | $71M | |
| PP&E (Net) | · | · | $36.0K | $41.0K | $47.0K | $52.0K | $57.0K | $62.0K | $67.0K | $73.0K | $78.0K | $125.0K | $328.0K | $345.0K | $357.0K | $338.0K | |
| PP&E (Gross) | · | · | $108.0K | $108.0K | $108.0K | $107.0K | $107.0K | $107.0K | $106.0K | $107.0K | $107.0K | $430.0K | $425.0K | $425.0K | $419.0K | $379.0K | |
| Accum. Depreciation | · | · | $72.0K | $67.0K | $61.0K | $55.0K | $50.0K | $45.0K | $39.0K | $34.0K | $29.0K | $305.0K | $97.0K | $80.0K | $62.0K | $41.0K | |
| Other Non-current Assets | $48.0K | $34.0K | $0 | $837.0K | $542.0K | $317.0K | $163.0K | $2M | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $3M | |
| Total Assets | $544M | $535M | $261M | $11M | $14M | $15M | $17M | $23M | $27M | $32M | $38M | $50M | $59M | $65M | $73M | $82M | |
| Accounts Payable | $3M | $819.0K | $444.0K | $520.0K | $756.0K | $354.0K | $377.0K | $503.0K | $724.0K | $2M | $2M | $4M | $6M | $4M | $3M | $2M | |
| Accrued Liabilities | $9M | $6M | $2M | $2M | $2M | $1M | $820.0K | $2M | $3M | $3M | $4M | $8M | $9M | $11M | $8M | $7M | |
| Current Liabilities | $28M | $24M | $20M | $3M | $3M | $2M | $1M | $2M | $4M | $4M | $6M | $13M | $15M | $14M | $11M | $9M | |
| Capital Leases | · | · | $53.0K | $57.0K | $60.0K | $60.0K | $61.0K | · | · | · | $66.0K | $112.0K | $206.0K | $234.0K | $328.0K | $440.0K | |
| Other Non-current Liabilities | $27.0K | $27.0K | $28.0K | $49.0K | $49.0K | $45.0K | $43.0K | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $28M | $24M | $20M | $3M | $3M | $2M | $1M | $2M | $4M | $4M | $6M | $13M | $15M | $14M | $11M | $9M | |
| Common Stock | $1.0K | $1.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Paid-in Capital | $932M | $894M | $311M | $292M | $292M | $292M | $292M | $291M | $290M | $289M | $288M | $287M | $285M | $281M | $280M | $278M | |
| Retained Earnings | $-546M | $-515M | $-487M | $-287M | $-283M | $-280M | $-278M | $-271M | $-267M | $-262M | $-256M | $-250M | $-241M | $-231M | $-218M | $-204M | |
| AOCI | $732.0K | $754.0K | $802.0K | $823.0K | $809.0K | $300.0K | $97.0K | $665.0K | $197.0K | $326.0K | $380.0K | $46.0K | $-137.0K | $-127.0K | $-244.0K | $-2M | |
| Stockholders' Equity | $516M | $512M | $240M | $8M | $11M | $14M | $16M | $21M | $24M | $28M | $32M | $37M | $44M | $50M | $62M | $73M | |
| Liabilities + Equity | $544M | $535M | $261M | $11M | $14M | $15M | $17M | $23M | $27M | $32M | $38M | $50M | $59M | $65M | $73M | $82M | |
| Shares Outstanding | 61,734,601 | 60,303,212 | 1,597,321 | 1,327,212 | 1,324,560 | 1,322,359 | 1,316,989 | 1,253,843 | 27,121,030 | 27,112,697 | 1,084,509 | 27,112,697 | 27,021,899 | 25,673,474 | 25,652,392 | 25,581,029 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $3M | $483.0K | $164.0K | $172.0K | $179.0K | $308.0K | $681.0K | $891.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Restructuring | · | · | · | · | · | · | $0 | $0 | $-2M | $3M | · | $3M | · | · | · | · | |
| Operating Cash Flow | $-22M | $-21M | $566.0K | $-3M | $-2M | $-2M | $-5M | $-4M | $-4M | $-6M | $-11M | $-8M | $-8M | $-9M | $-11M | $-10M | |
| CapEx | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $41.0K | $138.0K | |
| Investing Cash Flow | · | · | · | · | · | · | $0 | $0 | $6M | $6M | $10M | $8M | $3M | $1M | $14M | $8M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $171.0K | $3M | $23.0K | $65.0K | $424.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $23.0K | · | · | |
| Financing Cash Flow | $30M | $296M | · | · | · | · | · | · | · | · | $0 | $171.0K | $3M | $23.0K | $65.0K | $424.0K | |
| Taxes Paid | · | · | $0 | $0 | $3.0K | $2.0K | · | · | · | · | · | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -862.1% | -1003.6% | · | -7514.3% | -6842.0% | -3512.2% | · | -2630.1% | -2618.3% | -2233.8% | · | -1814.6% | -2524.7% | -3108.8% | · | -6163.8% | |
| Net Margin | -768.0% | -905.0% | · | -7459.5% | -6874.0% | -3423.0% | · | -2659.6% | -2506.1% | -2131.1% | · | -1720.1% | -2430.8% | -2994.0% | · | -6212.7% | |
| Pretax Margin | -761.7% | -903.6% | · | -7459.5% | -6866.0% | -3420.3% | · | -2654.8% | -2486.4% | · | · | · | · | · | · | · | |
| EBITDA Margin | -862.1% | -1003.6% | · | -7514.3% | -6842.0% | -3512.2% | · | -2630.1% | -2618.3% | -2233.8% | · | -1814.6% | -2524.7% | -3108.8% | · | -6163.8% | |
| ROA | -11.2% | -10.1% | · | -18.4% | -16.8% | -10.6% | · | -10.6% | -12.4% | -11.3% | · | -12.3% | -14.2% | -15.0% | · | -12.6% | |
| ROE | -11.8% | -10.6% | · | -21.6% | -19.9% | -12.1% | · | -13.3% | -15.9% | -14.0% | · | -14.8% | -16.7% | -17.1% | · | -13.6% | |
| ROIC | -6.8% | -6.0% | · | -39.4% | -31.3% | -19.0% | · | -18.4% | -23.8% | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 19.7 | 22.5 | · | 3.7 | 5.0 | 9.6 | · | 8.7 | 6.8 | 7.1 | · | 3.7 | 3.7 | 4.1 | · | 8.0 | |
| Quick Ratio | 19.6 | 22.4 | · | 2.9 | 3.9 | 7.7 | · | 8.1 | 6.2 | 6.3 | · | 3.5 | 3.5 | 3.8 | · | 7.8 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.36 | $8.48 | · | $6.03 | $8.27 | $10.37 | · | $16.70 | $0.87 | $1.04 | · | $1.38 | $1.62 | $1.96 | · | $2.84 | |
| Revenue / Share | $0.07 | $0.09 | · | $0.03 | $0.04 | $0.06 | · | $0.13 | $0.01 | $0.01 | · | $0.02 | $0.02 | $0.02 | · | $0.01 | |
| Cash Flow / Share | · | $-0.60 | · | · | · | $-1.84 | · | · | · | $-0.22 | · | · | · | $-0.36 | · | · | |
| Cash / Share | $8.76 | $8.84 | · | $5.73 | $7.71 | $9.03 | · | $15.69 | $0.84 | $0.78 | · | $0.85 | $0.85 | $0.98 | · | $1.11 | |
| Dividend / Share | $0.00 | $0.00 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $7.49 | $5.28 | · | $-12.05 | $-13.08 | $-15.40 | · | $-41.02 | $-45.13 | $-40.62 | · | $-8.97 | $-2.01 | $-2.27 | · | $-2.41 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $4M | · | $394.0K | $498.0K | $661.0K | · | $956.0K | $1M | $2M | · | $2M | $1M | $1M | · | $468.0K | |
| Net Income TTM | $-263M | $-235M | · | $-16M | $-17M | $-18M | · | $-21M | $-25M | $-31M | · | $-46M | $-52M | $-58M | · | $-61M | |
| Market Cap | $1.61B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 3.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/S | 196.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 3.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 3.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 28.8% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Betriebsgewinnmarge % | -18069.6% | -2637.4% | -2362.6% | -8477.4% | -33478.8% |
| Nettoergebnis | $-210M | $-21M | $-38M | $-62M | $-52M |
| Verwässerte EPS | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 13.0 | 14.1 | 6.3 | 5.8 | 24.2 |
| Quick Ratio | 12.8 | 11.8 | 5.7 | 5.4 | 22.0 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | · | · | · | $-43M | $-53M |
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Fairmount Healthcare Co-Invest V L.P., Peter Evan Harwin, Tomas Kiselak ×2 Einreichungen | 11. Februar 2026 | 19,99% | Änderung | · | SEC |
| Novo Holdings A/S ×6 Einreichungen | 9. Oktober 2025 | 0,00% | Änderung | · | SEC |
| OrbiMed Advisors LLC, OrbiMed Advisors Israel II Limited, OrbiMed Israel GP II, L.P., OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC, OrbiMed Capital LLC ×7 Einreichungen | 18. September 2023 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 25 Insider · 11 Führungskräfte · 14 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jennifer Jarrett | Director, President and CEO | 25. September 2026 P | 512.500 | 1 | 0 | $252.875 |
| Hans T. Schambye | Chief Executive Officer | 2. Januar 2026 M | 4.682 | 0 | 1 | $-14.966 |
| Lori Firmani | Chief Financial Officer | 2. Januar 2026 M | 931 | 0 | 1 | $-2.890 |
| Jonathan Freve | Chief Financial Officer | 3. Januar 2024 A | 12.000 | 0 | 0 | $0 |
| Sherwin Sattarzadeh | Chief Operating Officer | 5. Januar 2026 A | 190.376 | 0 | 0 | $0 |
| Anders Pedersen | Chief Operating Officer | 4. Januar 2023 A | 3.746 | 0 | 0 | $0 |
| Garrett Winslow | General Counsel | 3. Juli 2026 M | 2.289 | 0 | 2 | $-12.797 |
| Becker L. Hewes | Chief Medical Officer | 5. Januar 2026 A | 264.629 | 0 | 0 | $0 |
| Matthew Kronmiller | EVP Strategy and CBO | 3. Januar 2025 A | · | 0 | 0 | $0 |
| Stephanie Oestreich | Chief Business Officer | 4. Januar 2023 A | · | 0 | 0 | $0 |
| Bertil Lindmark | Chief Medical Officer | 4. Januar 2023 A | 16.604 | 0 | 0 | $0 |
| Julianne Bruno | Direktor | 23. März 2026 A | 137.032 | 0 | 0 | $0 |
| Christopher W. Cain | Direktor | 23. März 2026 A | · | 0 | 0 | $0 |
| Cameron Turtle | Direktor | 23. März 2026 A | · | 0 | 0 | $0 |
| Michael Landsittel | Direktor | 23. März 2026 A | · | 0 | 0 | $0 |
| Anne Prener | Direktor | 18. Juni 2025 A | · | 0 | 0 | $0 |
| Amy B Wechsler | Direktor | 18. Juni 2025 A | · | 0 | 0 | $0 |
| Jayson Donald Alexander Dallas | Direktor | 18. Juni 2025 A | · | 0 | 0 | $0 |
| Amit Munshi | Direktor | 18. Juni 2025 A | 4.793 | 0 | 0 | $0 |
| David Shapiro | Direktor | 18. Juni 2025 A | · | 0 | 0 | $0 |
| Carl Goldfischer | Direktor | 18. Juni 2025 A | 19.432 | 0 | 0 | $0 |
| Chau Quang Khuong | Direktor | 14. Juni 2023 A | 1.031.811 | 0 | 0 | $0 |
| Stephan Christgau | Direktor | 2. November 2020 C | 546.136 | 0 | 0 | $0 |
| Novo Holdings A/S | 10%-Eigentümer | 2. November 2020 C | 2.497.791 | 0 | 0 | $0 |
| Andrew Cheng | · | 12. August 2026 A | · | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 12 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IWO · iShares Trust | 0,06% | 344.459 SH | 11. September 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,06% | 39.408 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,05% | 1.358.452 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 307.241 SH | 19. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,03% | 14.454 SH | 19. August 2026 | Täglich |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,02% | 2.743 SH | 2. Oktober 2026 | Täglich |
| WSML · iShares Trust | 0,01% | 2.560 SH | 11. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 212.600 SH | 19. August 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 14.297 SH | 11. September 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 4.396 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 153.406 SH | 11. September 2026 | Täglich |
| ISCB · iShares Trust | · | 2.013 SH | 11. September 2026 | Täglich |
DMRA Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 16 Analysten
KAUF
Median-Ziel
$45.00
+117,9%
6 37,5%
Starker Kauf
9 56,2%
Kauf
1 6,2%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
9 Analysten · 2026-09-28Mittelwert-Ziel $46.89 +127,1%
← Unter allen Zielen
Aktueller Preis $20.65
Tief$40.00
Mittelwert$46.89
Hoch$60.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| DMRA | · | · | 38.3% | -17981.1% | -167.0% | · |
| KLRA | · | · | · | · | · | · |
| ORIC | $806M | -5.6 | · | · | -36.5% | · |
| REPL | $633M | -2.3 | · | · | -146.2% | · |
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | · |
| BCAX | $953M | -6.7 | · | · | -33.0% | · |
| TRAX | · | · | · | · | · | · |
| VOR | $506M | -0.2 | · | · | 83.4% | · |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 10, 2026